We are live on ! Find out more
EIDX

Eidos Therapeutics, Inc. Common Stock
EIDX

Delisted

EIDX was delisted on the 25th of January, 2021.

Back to rankings

58 hedge funds and large institutions have $94.3M invested in Eidos Therapeutics, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 19 increasing their positions, 6 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

217% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 6

93% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 14

29% more funds holding

Funds holding: 45 → 58 (+13)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

46% less capital invested

Capital invested by funds: $174M → $94.3M (-$79.7M)

Holders
58
Holders Change
+13
Holders Change %
+28.89%
% of All Funds
1.33%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
27
Increased
19
Reduced
6
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RG
Redmile Group
California
+$11.1M
2
BlackRock
BlackRock
New York
+$9.5M
3
FCMI
Foresite Capital Management IV
California
+$4.6M
4
AIG
American International Group
New York
+$3.94M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2.44M

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$6.51M
2
Millennium Management
Millennium Management
New York
-$5.71M
3
MWNA
Marshall Wace North America
New York
-$4.31M
4
EAM
Eventide Asset Management
Massachusetts
-$3.29M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.95M
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$21.6M – – –
Viking Global Investors
2
Viking Global Investors
Connecticut
$19.8M – – –
RG
3
Redmile Group
California
$8.66M +$11.1M +676,700 +354%
BlackRock
4
BlackRock
New York
$7.26M +$9.5M +577,698 +385%
PA
5
Perceptive Advisors
New York
$6.86M – – –
FCMI
6
Foresite Capital Management IV
California
$5.24M +$4.6M +279,918 +114%
DM
7
Deerfield Management
New York
$4.2M +$1.59M +96,602 +30%
CAM
8
Cormorant Asset Management
Massachusetts
$3.85M – – –
BOTOTLSJU
9
Board of Trustees of The Leland Stanford Junior University
California
$2.65M +$1.42M +86,598 +48%
AIG
10
American International Group
New York
$2.39M +$3.94M +239,812 New
HIM
11
Hillhouse Investment Management
Cayman Islands
$2.25M – – –
Vanguard Group
12
Vanguard Group
Pennsylvania
$1.98M +$2.44M +148,673 +297%
Northern Trust
13
Northern Trust
Illinois
$898K +$1.25M +76,182 +551%
SM
14
Sabby Management
Florida
$766K +$442K +26,907 +54%
OAM
15
Oxford Asset Management
United Kingdom
$650K -$1.27M -77,160 -54%
LCM
16
Laurion Capital Management
New York
$499K – – –
Balyasny Asset Management
17
Balyasny Asset Management
Illinois
$320K -$797K -48,505 -60%
SFM
18
Sphera Funds Management
Israel
$315K +$340K +20,694 +191%
Charles Schwab
19
Charles Schwab
California
$315K +$518K +31,534 New
Geode Capital Management
20
Geode Capital Management
Massachusetts
$312K +$515K +31,362 New
TCM
21
Tekla Capital Management
Massachusetts
$278K +$459K +27,900 New
State Street
22
State Street
Massachusetts
$266K +$437K +26,600 New
Point72 Asset Management
23
Point72 Asset Management
Connecticut
$223K -$2.95M -179,404 -89%
TAM
24
Tiverton Asset Management
Delaware
$216K +$223K +13,595 +169%
WC
25
Wexford Capital
Florida
$200K +$329K +20,000 New
1
2 3

EIDX Hedge Fund Activity: Q3 2018 in Review

58 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Eidos Therapeutics, Inc. Common Stock (EIDX) for Q3 2018, worth a combined $94.3M — down 46% from $174M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new EIDX positions and 14 closed out — a net gain of 13 holders — while 19 added to existing stakes and 6 trimmed.

The largest buyer was Redmile Group, adding an estimated $11.1M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $6.51M sold.

  • 58 institutional investors held Eidos Therapeutics, Inc. Common Stock (EIDX) as of Q3 2018, up from 45 in Q2 2018.
  • Funds reported $94.3M of Eidos Therapeutics, Inc. Common Stock stock for Q3 2018, down 46% quarter-over-quarter.
  • 27 funds opened new Eidos Therapeutics, Inc. Common Stock positions in Q3 2018 and 14 closed out, a net change of +13 holders.
  • The largest Eidos Therapeutics, Inc. Common Stock buyer in Q3 2018 was Redmile Group, an estimated $11.1M added.
  • The largest Eidos Therapeutics, Inc. Common Stock seller in Q3 2018 was Janus Henderson Group, an estimated $6.51M sold.

Based on aggregated 13F filings for Q3 2018.